Upcoming conferences
13/11/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231113:nRSM1598Ta&default-theme=true
RNS Number : 1598T Evgen Pharma PLC 13 November 2023
Evgen Pharma plc
("Evgen" or the "Company")
Attendance at upcoming investor conferences
Alderley Park, UK - 13 November 2023: Evgen Pharma plc (AIM: EVG), a clinical
stage drug development
company developing sulforaphane-based medicines for the treatment of cancer
and other indications, notes that members of its executive team will be
participating in the following investor events:
· LSX Inv€$stival Showcase
(https://www.lsxleaders.com/investival-showcase?utm_term=investival&utm_campaign=xx_LSX_HCC&utm_source=adwords&utm_medium=ppc&hsa_tgt=kwd-1965383317193&hsa_grp=153641181764&hsa_src=g&hsa_net=adwords&hsa_mt=b&hsa_ver=3&hsa_ad=668182574603&hsa_acc=7380976740&hsa_kw=investival&hsa_cam=20425485043&gclid=Cj0KCQjwqP2pBhDMARIsAJQ0CzriJYaYYL2zyE8gwD8r4HO2PQYAczJQrzRUhgpcbezPWDPFZH2_k4gaAgabEALw_wcB)
, Monday 13 November 2023, London
Huw Jones (CEO) and Helen Kuhlman (CBO) will be attending, and Huw Jones will
be presenting on Stage 4: Biotech Public Stage at 13:45
· Jefferies London Healthcare Conference, 14-16 November 2023, London
Huw Jones (CEO) and Helen Kuhlman (CBO) will be attending
· Members of the Evgen Pharma executive team will be attending the JP
Morgan Healthcare Conference and Biotech Showcase
(https://informaconnect.com/biotech-showcase/) on 8-11 January 2024 in San
Francisco
If you would like to meet the team at any of these events, please contact the
Company via email at enquiries@evgen.com.
Please refer to the conference websites for further information and up to date
schedules.
-Ends-
Enquiries:
Evgen Pharma plc +44 1625 466591
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
Cavendish (Nominated Advisor and Broker) +44 20 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Nigel Birks (ECM)
Instinctif Partners +44 207 457 2020
evgen@instinctif.com
Melanie Toyne-Sewell / Rozi Morris / Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing
sulforaphane based medicines for the treatment of multiple diseases. The
Company's core technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane and novel
proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b
study of the Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be
investigated initially in this indication as an investigator sponsored study
in the Netherlands.
The Company also has a wide number of collaborations with leading academic
centres in the UK, Europe and the US as part of the continuing strategy to
build the scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum disorder. The
deal, if successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com (http://www.evgen.com)
.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRABUBDBRUBDGXD